The uses of systemic chemotherapeutic agents in psoriasis.
D000287:Administration, Topical; D000875:Anthralin / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001380:Azauridine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D009150:Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*
D009150:Mustard Compounds; D001380:Azauridine; D015122:Mercaptopurine; D009173:Mycophenolic Acid; C100231:azaribine; D001379:Azathioprine; D000875:Anthralin; D006918:Hydroxyurea